Related Experiment Video

Updated: May 27, 2025

Antigen-Capture Enzyme-Linked Immunosorbent Assay for Specific Detection of Mycoplasma pneumoniae
06:04

Antigen-Capture Enzyme-Linked Immunosorbent Assay for Specific Detection of Mycoplasma pneumoniae

Published on: February 24, 2023

2.3K

Clinical Features and Management Strategies in Children With Mycoplasma Pneumoniae

Tamara Garcia1, Todd A Florin2, Jan Leonard1

  • 1Department of Pediatrics, Children's Hospital Colorado and University of Colorado, Aurora, CO.

Pediatric Emergency Care
|February 17, 2025
PubMed

Insights

Mycoplasma pneumoniae (Mp) community-acquired pneumonia (CAP) in children presents similarly to non-Mp CAP but may involve older children. Polymerase chain reaction testing is key for diagnosis, as clinical outcomes are comparable.

Area of Science:

  • Pediatric infectious diseases
  • Respiratory infections
  • Microbiology

Background:

  • Mycoplasma pneumoniae (Mp) is a frequent cause of community-acquired pneumonia (CAP) in children.
  • Differentiating Mp CAP from other causes clinically is challenging.

Purpose of the Study:

  • To compare clinical presentation, management, and outcomes of pediatric Mp CAP versus non-Mp CAP.
  • To identify factors distinguishing Mp CAP in children.

Main Methods:

  • Prospective multicenter cohort study of children (≥2 months) with CAP.
  • Exclusion of children with complex chronic conditions.
  • Polymerase chain reaction (PCR) testing for Mp detection.
  • Analysis of clinical outcomes including hospitalization, PICU admission, and rehospitalization.

Main Results:

  • 38 of 415 children (7.4%) had Mp detected.
  • Children with Mp CAP were older and more likely to receive azithromycin or prior antibiotics.
  • No statistical differences in symptom prevalence, lab values, or radiographic findings.
  • Children with Mp CAP had a 33% shorter hospital stay.

Conclusions:

  • Clinical presentation and outcomes for pediatric Mp CAP are similar to non-Mp CAP.
  • PCR testing is crucial for accurate Mp CAP diagnosis.
  • While symptom duration may be longer, clinical outcomes do not significantly differ.
Abstract

More Related Videos

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

15.0K
Osteopathic Manipulative Treatment as a Useful Adjunctive Tool for Pneumonia13:27

Osteopathic Manipulative Treatment as a Useful Adjunctive Tool for Pneumonia

Published on: May 6, 2014

47.8K

Related Concept Videos

Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
287
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
1.8K
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
146
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
173
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
201
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
139